Generic Name and Formulations:
Gatifloxacin 0.3%; oph soln; contains benzalkonium chloride.
Indications for ZYMAR:
Susceptible infections of the conjunctiva.
Adults and Children:
<1yr: not established. ≥1yr: 1 drop every 2 hours while awake for 2 days (up to 8 times daily), then 1 drop 4 times daily while awake for 5 more days.
Remove contact lenses. Risk of corneal endothelial cell injury: do not administer into anterior chamber of the eye. Discontinue if superinfection or hypersensitivity occurs. Pregnancy. Nursing mothers.
Conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, conjunctival hemorrhage, dry or red eye, eye discharge or pain, eyelid edema, headache, reduced visual acuity, taste disturbance.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics